跳至主要内容
临床试验/NCT01707628
NCT01707628已完成不适用

Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab

St. Antonius Hospital8 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2012年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
98
试验地点
8
主要终点
Influenza antibody titre

研究概览

简要总结

The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma. Secondly to study the immune-response to vaccination with influenza virus vaccine, after treatment with rituximab in relation to the reconstitution of immune-function.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with non-Hodgkin's lymphoma, treated with rituximab (with a range of 6-12 cycles) and who are in remission.
  • Completion of rituximab therapy in the last twelve months before start of the study.
  • Age ≥ 18 years.
  • Signing of informed consent.

排除标准

  • Completion of rituximab therapy 7-8 months before start of the study.
  • Fever at time of vaccination.
  • Previous/known allergic reaction to any of the components of the vaccines given.

结局指标

主要结局

Influenza antibody titre

时间窗: 3 weeks after vaccination

次要结局

  • immunoglobulin levels(6 months)
  • IgG subclasses(6 months)
  • production of IFN-γ by CD4+ cells(6 months)
  • Cytokines(6 months)
  • genetic factors(6 months)
  • lymphocyte subsets(6 months)
  • number of memory B cells(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

M. Rab

Drs.

St. Antonius Hospital

研究点 (8)

Loading locations...

相似试验